An observational study in Chronic Inflammatory Demyelinating Polyneuropathy, sponsored by Centre Hospitalier Universitaire de Liege. Recruiting at 1 site in Belgium. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-02-12.
Sponsored by Centre Hospitalier Universitaire de Liege · Observational
Among 15 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in Belgium — 4 open to participants now, 6 under way, 3 of them phase 3. Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · Belgium.
Among the 15 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in Belgium, this one is the only one that started in 2023, is the only observational one, and was the 10th registered.
137 studies on the registry are indexed under Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; 51 are open to participants now.
Browse Polyradiculoneuropathy, Chronic Inflammatory Demyelinating studies →4 of the 15 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in Belgium are open now. Recruiting first, the newest first:
Immunovant Sciences GmbH · Sites in Belgium, United States, Argentina and 27 more countries
Ages 18+
Dianthus Therapeutics · Sites in Belgium, United States, Argentina and 28 more countries
Ages 18–75
Sanofi · Sites in Belgium, United States, Argentina and 21 more countries
Ages 18+
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 36 Polyradiculoneuropathy, Chronic Inflammatory Demyelinating studies recruiting now, 24 (67%) set no upper age limit and 9 (25%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 49 across 44 observational studies indexed under Polyradiculoneuropathy, Chronic Inflammatory Demyelinating.
Median enrollment 108 across the 14 interventional studies, 40 across the 1 observational. Of the 9 that completed or were terminated, 7 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 15 have an industry lead sponsor. The 10 most frequent:
Centre Hospitalier Universitaire de Liege is the lead sponsor of 40 studies on the registry; 26 are open to participants now.
Centre Hospitalier Universitaire de Liege has 1 study filed under Polyradiculoneuropathy, Chronic Inflammatory Demyelinating — fewer than ten, so there is no comparison to draw.
2 of the studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in Belgium that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06290141Phase 3SanofiA Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | 2027-07-09 |
| NCT04280718argenxA Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) | 2027-04-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 15 studies in Polyradiculoneuropathy, Chronic Inflammatory Demyelinating with a site in Belgium, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
ActiCIDP is a monocentric academic study. Patients with Chronic inflammatory demyelinating polyradiculoneuritis may be included on a voluntary basis.
The investigators plan to include a group of approximately 40 patients with CIDP.
The investigators have planned to assess patient every three months for a year. After each visit, participants will wear Actimyo for one month daily.
On each visit, participants will undergo a clinical examination with MRC sum score, a mISS score and a I-RODS score.
They will perform few tests 6-minutes walk test (6MWT), a myogrip measurement, and a 9 Hole Peg Test (9HPT) and will answer to some questionaires (mISS, INCAT and PGIC).
Actimyo is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
Adults patients with Chronic inflammatory demyelinating polyradiculoneuritis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will wear 2 Actimyos in everyday life. Actimyo is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
95th centile of stride velocity
95th centile of stride velocity obtained with a magneto-inertial sensor (Actimyo) in real-life (meter per second).
Time frame: 1 year
50th centile of stride velocity
50th centile of stride velocity obtained with a magneto-inertial sensor (Actimyo) in real-life (meter per second).
Time frame: 1 year
95th centile of stride length
95th centile of stride length obtained with a magneto-inertial sensor (Actimyo) in real-life (meter).
Time frame: 1 year
50th centile of stride length
50th centile of stride length obtained with a magneto-inertial sensor (Actimyo) in real-life (meter).
Time frame: 1 year
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2023 (actual). Primary completion is estimated for Jan 2028, 53 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating →
Centre Hospitalier Universitaire de Liege